OBJECTIVE:Adjunctive-to-insulin therapy with sodium-glucose cotransporter 2 (SGLT2) inhibition may improve glycemic control in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: We evaluated the glycemic efficacy and safety of empagliflozin 25 mg daily in 40 patients treated for 8 weeks in a single-arm open-label proof-of-concept trial (NCT01392560). RESULTS:Mean A1C decreased from 8.0 ± 0.9% (64 ± 10 mmol/mol) to 7.6 ± 0.9% (60 ± 10 mmol/mol) (P < 0.0001), fasting glucose from 9.0 ± 4.3 to 7.0 ± 3.2 mmol/L (P = 0.008), symptomatic hypoglycemia (<3.0 mmol/L) from 0.12 to 0.04 events per patient per day (P = 0.0004), and daily insulin dose from 54.7 ± 20.4 to 45.8 ± 18.8 units/day (P < 0.0001). Mean urinary excretion of glucose increased from 19 ± 19 to 134 ± 61 g/day (P < 0.0001). Weight decreased from 72.6 ± 12.7 to 70.0 ± 12.3 kg (P < 0.0001), and waist circumference decreased from 82.9 ± 8.7 to 79.1 ± 8.0 cm (P < 0.0001). CONCLUSIONS: This proof-of-concept study strongly supports a randomized clinical trial of adjunctive-to-insulin empagliflozin in patients with T1D.
RCT Entities:
OBJECTIVE: Adjunctive-to-insulin therapy with sodium-glucose cotransporter 2 (SGLT2) inhibition may improve glycemic control in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: We evaluated the glycemic efficacy and safety of empagliflozin 25 mg daily in 40 patients treated for 8 weeks in a single-arm open-label proof-of-concept trial (NCT01392560). RESULTS: Mean A1C decreased from 8.0 ± 0.9% (64 ± 10 mmol/mol) to 7.6 ± 0.9% (60 ± 10 mmol/mol) (P < 0.0001), fasting glucose from 9.0 ± 4.3 to 7.0 ± 3.2 mmol/L (P = 0.008), symptomatic hypoglycemia (<3.0 mmol/L) from 0.12 to 0.04 events per patient per day (P = 0.0004), and daily insulin dose from 54.7 ± 20.4 to 45.8 ± 18.8 units/day (P < 0.0001). Mean urinary excretion of glucose increased from 19 ± 19 to 134 ± 61 g/day (P < 0.0001). Weight decreased from 72.6 ± 12.7 to 70.0 ± 12.3 kg (P < 0.0001), and waist circumference decreased from 82.9 ± 8.7 to 79.1 ± 8.0 cm (P < 0.0001). CONCLUSIONS: This proof-of-concept study strongly supports a randomized clinical trial of adjunctive-to-insulinempagliflozin in patients with T1D.
Authors: Marko Skrtić; Gary K Yang; Bruce A Perkins; Nima Soleymanlou; Yuliya Lytvyn; Maximilian von Eynatten; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Thomas Hach; Melvin Silverman; David Z I Cherney Journal: Diabetologia Date: 2014-10-04 Impact factor: 10.122
Authors: Megan E Capozzi; Reilly W Coch; Jepchumba Koech; Inna I Astapova; Jacob B Wait; Sara E Encisco; Jonathan D Douros; Kimberly El; Brian Finan; Kyle W Sloop; Mark A Herman; David A D'Alessio; Jonathan E Campbell Journal: Diabetes Date: 2020-01-31 Impact factor: 9.461
Authors: Kathryn M Thrailkill; Jeffry S Nyman; R Clay Bunn; Sasidhar Uppuganti; Katherine L Thompson; Charles K Lumpkin; Evangelia Kalaitzoglou; John L Fowlkes Journal: Bone Date: 2016-10-28 Impact factor: 4.398
Authors: Kathryn M Thrailkill; R Clay Bunn; Jeffry S Nyman; Mallikarjuna R Rettiganti; Gael E Cockrell; Elizabeth C Wahl; Sasidhar Uppuganti; Charles K Lumpkin; John L Fowlkes Journal: Bone Date: 2015-07-23 Impact factor: 4.398